

**Disclaimer:** The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.

**Activities/persons addressed by this document:** This document addresses coverage of items and services related to diagnostic testing for COVID-19 and coverage of qualifying coronavirus preventive services, including recommended COVID-19 vaccines. The persons addressed by this document are group health plans, health insurance issuers offering group or individual health insurance coverage, and providers of COVID-19 related services to the uninsured.

**Date of document issuance:** February 26, 2021

**Replacement / Revision Status:** This document provides new guidance and clarifies previous guidance in FAQs about Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Part 43.

**Agency Identifier:** CCIIO OG 1081

**Summary of Document:** This document addresses the requirement under section 6001 of the Families First Coronavirus Response Act (FFCRA), as amended by section 3201 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), for group health plans and health insurance issuers offering group or individual health insurance coverage, including grandfathered health plans, to provide benefits for certain items and services related to diagnostic testing for COVID-19, without imposing any cost-sharing requirements, prior authorization, or other medical management requirements. In addition, this document addresses the requirement under section 3203 of the CARES Act for non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual health insurance coverage to cover, without cost sharing, qualifying coronavirus preventive services, including recommended COVID-19 vaccines. This document also addresses other health coverage issues related to COVID-19 and includes information about how providers may seek federal reimbursement when delivering COVID-19 related services to the uninsured.

**Citation to statutory provision / regulation applicable to this document:**

- Section 6001 of the FFCRA, as amended by section 3201 of the CARES Act
- Sections 3202 and 3203 of the CARES Act
- Sections 2713, 2715(d)(4), 2719, 2722, 2763, and 2791(c) of the Public Health Service Act
- 45 CFR 146.145(b)(3)(vi), 147.200(b), and 147.130

# FAQS ABOUT FAMILIES FIRST CORONAVIRUS RESPONSE ACT AND CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT IMPLEMENTATION PART 44

February 26, 2021

Set out below are Frequently Asked Questions (FAQs) regarding implementation of the Families First Coronavirus Response Act (FFCRA), the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), and other health coverage issues related to coronavirus disease 2019 (COVID-19). These FAQs have been prepared jointly by the Departments of Labor, Health and Human Services (HHS), and the Treasury (collectively, the Departments). Like previously issued FAQs (available at <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employersand-advisers/aca-implementation-faqs> and <http://www.cms.gov/ccio/resources/fact-sheets-and-faqs/index.html>), these FAQs answer questions from stakeholders to help people understand the law and benefit from it, as intended.

## **The FFCRA and the CARES Act**

### *COVID-19 Diagnostic Testing*

The FFCRA was enacted on March 18, 2020.<sup>1</sup> Section 6001 of the FFCRA generally requires group health plans and health insurance issuers offering group or individual health insurance coverage, including grandfathered health plans, to provide benefits for certain items and services related to testing for the detection of SARS-CoV-2, which is the virus that causes COVID-19, or the diagnosis of COVID-19 when those items or services are furnished on or after March 18, 2020, and during the applicable emergency period.<sup>2</sup> Under the FFCRA, plans and issuers must

---

<sup>1</sup> Pub. L. No. 116-127 (2020).

<sup>2</sup> On January 31, 2020, HHS Secretary Alex M. Azar II declared that as of January 27, 2020, a public health emergency exists nationwide as the result of the 2019 novel coronavirus. See HHS Office of the Assistant Secretary for Preparedness and Response, Determination of the HHS Secretary that a Public Health Emergency Exists, available at <https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx>. On January 7, 2021, the HHS Secretary renewed the COVID-19 public health emergency declaration, effective January 21, 2021, that was previously renewed on April 21, 2020, July 23, 2020, and October 2, 2020. See HHS Office of the Assistant Secretary for Preparedness and Response, Renewal of Determination That A Public Health Emergency Exists, available at <https://www.phe.gov/emergency/news/healthactions/phe/Pages/covid19-07Jan2021.aspx>. The Secretary may extend the public health emergency declaration for subsequent 90-day periods for as long as the public health emergency continues to exist, and may terminate the declaration whenever he determines that the public health emergency has ceased to exist. On January 22, 2021, Acting HHS Secretary Norris Cochran sent a letter to governors announcing that HHS has determined that the public health emergency will likely remain in place for the

provide this coverage without imposing any cost-sharing requirements (including deductibles, copayments, and coinsurance), prior authorization, or other medical management requirements.

The CARES Act was enacted on March 27, 2020.<sup>3</sup> Section 3201 of the CARES Act amended section 6001 of the FFCRA to include a broader range of diagnostic items and services that plans and issuers must cover without any cost-sharing requirements, prior authorization, or other medical management requirements. Section 3202(a) of the CARES Act generally requires plans and issuers providing coverage for these items and services to reimburse any provider of COVID-19 diagnostic testing an amount that equals the negotiated rate or, if the plan or issuer does not have a negotiated rate with the provider, the cash price for such service that is listed by the provider on a public website. (The plan or issuer may negotiate a rate with the provider that is lower than the cash price.) Additionally, during the public health emergency related to COVID-19 declared under section 319 of the Public Health Service Act (PHS Act) (referred to in this document as the PHE for COVID-19), section 3202(b) of the CARES Act and implementing regulations at 45 CFR Part 182 require providers of diagnostic tests for COVID-19 to make public the cash price of a COVID-19 diagnostic test on the provider's public internet website or face potential enforcement action including civil monetary penalties.

Under section 6001(c) of the FFCRA, the Departments are authorized to implement the requirements of section 6001 of the FFCRA, as amended by section 3201 of the CARES Act, through sub-regulatory guidance, program instruction, or otherwise. The Departments have previously issued two sets of FAQs to implement these provisions of the FFCRA and CARES Act and address other health coverage issues related to COVID-19.

**Q1. Under the FFCRA, can plans and issuers use medical screening criteria to deny (or impose cost sharing on) a claim for COVID-19 diagnostic testing for an asymptomatic person who has no known or suspected exposure to COVID-19?**

No. The FFCRA prohibits plans and issuers from imposing medical management, including specific medical screening criteria, on coverage of COVID-19 diagnostic testing. Plans and issuers cannot require the presence of symptoms or a recent known or suspected exposure, or otherwise impose medical screening criteria on coverage of tests.

When an individual seeks and receives a COVID-19 diagnostic test from a licensed or authorized health care provider, or when a licensed or authorized health care provider refers an individual for a COVID-19 diagnostic test, plans and issuers generally must assume that the receipt of the

---

entirety of 2021, and when a decision is made to terminate the declaration or let it expire, HHS will provide states with 60 days' notice prior to termination.

<sup>3</sup> Pub. L. No. 116-136 (2020).

test reflects an “individualized clinical assessment” and the test should be covered without cost sharing, prior authorization, or other medical management requirements.<sup>4</sup>

This FAQ clarifies the Departments’ guidance in FAQs Part 43, Q5,<sup>5</sup> with respect to the testing of asymptomatic individuals with no known or suspected exposure to COVID-19. This FAQ does not modify previous guidance addressing coverage of testing for groups of asymptomatic employees or individuals with no known or suspected recent exposure to COVID-19, such as for public health surveillance or employment purposes (see Q2 below).

State and local public health authorities retain the authority to direct providers to limit eligibility for testing based on clinical risk or other criteria to manage testing supplies and access to testing. Responsibility for implementing such state or local limits on testing falls on attending health care providers, not on plans and issuers. Plans and issuers may not use such criteria to deny (or impose cost sharing on) a claim for COVID-19 diagnostic testing.

**Q2. May plans and issuers distinguish between COVID-19 diagnostic testing of asymptomatic people that must be covered, and testing for general workplace health and safety, for public health surveillance, or for other purposes not primarily intended for individualized diagnosis or treatment of COVID-19?**

Yes. Plans and issuers must provide coverage without imposing any cost-sharing requirements (including deductibles, copayments, and coinsurance), prior authorization, or other medical management requirements for COVID-19 diagnostic testing of asymptomatic individuals when the purpose of the testing is for individualized diagnosis or treatment of COVID-19. However, plans and issuers are not required to provide coverage of testing such as for public health surveillance or employment purposes. But there is also no prohibition or limitation on plans and issuers providing coverage for such tests. Plans and issuers are encouraged to ensure communications about the circumstances in which testing is covered are clear. To the extent not inconsistent with the FFCRA’s prohibition on medical management, plans and issuers may continue to employ programs designed to detect and address fraud and abuse.

**Q3. Under the FFCRA, are plans and issuers required to cover COVID-19 diagnostic tests provided through state- or locality-administered testing sites?**

Yes. As stated in FAQs Part 43, Q3, any health care provider acting within the scope of their license or authorization can make an individualized clinical assessment regarding COVID-19 diagnostic testing.<sup>6</sup> If an individual seeks and receives a COVID-19 diagnostic test from a

---

<sup>4</sup> See FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Part 43, Q3 (June 23, 2020), available at <https://www.cms.gov/files/document/FFCRA-Part-43-FAQs.pdf> and <https://www.dol.gov/sites/dolgov/files/ebsa/about-ebsa/our-activities/resource-center/faqs/aca-part-43.pdf>.

<sup>5</sup> *Id.* at Q5.

<sup>6</sup> *Supra* note 4.

licensed or authorized provider, including from a state- or locality-administered site, a “drive-through” site, and/or a site that does not require appointments, plans and issuers generally must assume that the receipt of the test reflects an “individualized clinical assessment.”

**Q4. Do point-of-care tests for COVID-19 have to be covered without cost sharing under the FFCRA?**

Yes. The FFCRA and the CARES Act make no distinction between point-of-care and other tests; all COVID-19 diagnostic tests that meet one of the criteria outlined in section 6001 of the FFCRA, as amended by section 3201 of the CARES Act, must be covered without cost sharing, prior authorization, or medical management (including for asymptomatic individuals with no known or suspected exposure to COVID-19).

**Q5. What items and services are plans and issuers required to cover associated with COVID-19 diagnostic testing? What steps should plans and issuers take to help ensure compliance with these requirements?**

As the Departments previously explained, “[s]ection 6001(a)(2) of the FFCRA requires plans and issuers to provide coverage for items and services furnished to an individual during health care provider office visits (including in-person visits and telehealth visits), urgent care center visits, and emergency room visits that result in an order for or administration of an *in vitro* diagnostic product, but only to the extent that the items and services relate to the furnishing or administration of the product or to the evaluation of the individual for purposes of determining the need of the individual for that product.”<sup>7</sup>

Plans and issuers should maintain their claims processing and other information technology systems in ways that protect participants, beneficiaries, and enrollees from inappropriate cost sharing and should document any steps that they are taking to do so. The Departments invite feedback from stakeholders on additional steps that plans and issuers should take to protect their participants, beneficiaries, and enrollees from inappropriate cost sharing and ensure compliance with the law. The Departments will take enforcement action, where appropriate, to ensure consumers receive the protections they are entitled to under the FFCRA and CARES Act.

**Q6. What should plans and issuers do if they identify providers of COVID-19 diagnostic testing who are not complying with requirements under section 3202(b) of the CARES Act related to cash price posting or who are otherwise acting in bad faith?**

Although it is the Departments’ understanding that most providers have been pricing COVID-19 tests at reasonable levels, generally consistent with reimbursement rates set by the Medicare program, the Departments are aware that some providers have not done so and are using the public health emergency as an opportunity to impose extraordinarily high charges. One way

---

<sup>7</sup> See FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Part 43, Q7.

plans and issuers can respond to such practices is by giving participants, beneficiaries, and enrollees information about providers who have negotiated rates for COVID-19 testing with the plan or issuer, or about other providers who adhere to best practice standards, and encouraging participants, beneficiaries, and enrollees to rely on these providers. Plans and issuers that identify providers that are violating the cash price posting requirements should report violations to [COVID19CashPrice@cms.hhs.gov](mailto:COVID19CashPrice@cms.hhs.gov).

The Departments welcome feedback from stakeholders on how best to monitor abusive practices and on ways to encourage consumers to get tested by providers that are not overcharging for their services or otherwise violating the law.

### *Rapid Coverage of Preventive Services for Coronavirus*

Section 3203 of the CARES Act and its implementing regulations<sup>8</sup> require non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual health insurance coverage to cover, without cost-sharing requirements, any qualifying coronavirus preventive services pursuant to section 2713(a) of the PHS Act and its implementing regulations (or any successor regulations). The term “qualifying coronavirus preventive service” means an item, service, or immunization that is intended to prevent or mitigate COVID-19 and that is, with respect to the individual involved—

- An evidence-based item or service that has in effect a rating of “A” or “B” in the current recommendations of the United States Preventive Services Task Force (USPSTF); or
- An immunization that has in effect a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) (regardless of whether the immunization is recommended for routine use).

As of the publication of this document, there are two COVID-19 vaccines that have received a recommendation from ACIP. On December 12, 2020, ACIP issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine for persons 16 years of age and older in the U.S. population under the FDA’s emergency use authorization (EUA). The recommendation was adopted by the Director of the CDC on December 13, 2020. On December 19, 2020, ACIP issued an interim recommendation for use of the Moderna COVID-19 vaccine for persons 18 years of age and older in the U.S. population under the FDA’s EUA. The recommendation was adopted by the Director of the CDC on December 20, 2020.<sup>9</sup>

---

<sup>8</sup> 85 FR 71142 (Nov. 6, 2020).

<sup>9</sup> Ctrs. for Disease Control & Prevention, COVID-19 ACIP Vaccine Recommendations, available at <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>.

**Q7. Do plans and issuers have to cover all COVID-19 vaccines with a recommendation in effect from ACIP (and associated administration)?**

Yes. Plans and issuers must provide coverage without cost sharing for all COVID-19 vaccines that have received a recommendation that makes them a qualifying coronavirus preventive service with respect to the individual involved, and their administration. Plans and issuers are not permitted to exclude coverage for (or impose cost sharing on) any qualifying coronavirus preventive services.<sup>10</sup>

**Q8. When must plans and issuers begin providing coverage for qualifying coronavirus preventive services?**

Plans and issuers must cover qualifying coronavirus preventive services without cost sharing starting no later than 15 business days (not including weekends or holidays) after the date the USPSTF or ACIP makes an applicable recommendation regarding a qualifying coronavirus preventive service. A recommendation from ACIP is considered in effect after it has been adopted by the Director of the CDC. Thus, the requirement to cover the Pfizer BioNTech COVID-19 vaccine became effective January 5, 2021, and the requirement to cover the Moderna COVID-19 vaccine became effective January 12, 2021.

**Q9. Do plans and issuers have to cover the vaccine administration fee when the plan or issuer is not billed for the vaccine?**

Yes. As the Departments previously explained in the preamble to the Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency interim final rule with request for comments, plans and issuers subject to section 2713 of the PHS Act must cover without cost sharing an immunization that is a qualifying coronavirus preventive service and its administration, regardless of how the administration is billed, and regardless of whether a COVID-19 vaccine or any other immunization requires the administration of multiple doses in order to be considered a complete vaccination. This includes covering without cost sharing the administration of a required preventive immunization in instances where a third party, such as the Federal Government, pays for the preventive immunization.<sup>11</sup>

**Q10. The CDC and ACIP have made recommendations regarding the categories of individuals to prioritize for vaccination during the initial phases of the COVID-19 vaccination program while vaccine supply is limited.<sup>12</sup> May a plan or issuer deny coverage of recommended COVID-19 vaccines because a participant, beneficiary, or enrollee is not in a category recommended for early vaccination?**

---

<sup>10</sup> 26 CFR 54.9815-2713T(a)(1)(v)(B); 29 CFR 2590.715-2713(a)(1)(v)(B); 45 CFR 147.130(a)(1)(v)(B).

<sup>11</sup> 85 FR at 71174–75.

<sup>12</sup> COVID-19 ACIP Vaccine Recommendations, *supra* note 9.

No. While certain individuals may be prioritized by states and local jurisdictions for early vaccination, ACIP does not currently recommend against vaccination of individuals in other prioritization categories. Plans and issuers must provide coverage without cost sharing of COVID-19 immunizations in accordance with the vaccine-specific recommendations of ACIP that have been adopted by the Director of the CDC, regardless of priority. Those ACIP recommendations currently recommend vaccination of all individuals in the specified age groups noted in the introduction to this section.

Plans and issuers may communicate with participants, beneficiaries, or enrollees about which individuals will be vaccinated first when supply is limited. However, a plan or issuer should not communicate that coverage is limited only to individuals who are recommended for early vaccination based on state and local plans for allocation of initial doses of the COVID-19 vaccine or the CDC and ACIP recommendations regarding which categories of individuals to prioritize for vaccination.

Furthermore, a decision by an individual's provider (including a provider integrated with a health plan) to decline to give the vaccine to someone because he or she is not within a prioritization category is not an adverse benefit determination made by a group health plan or health insurance issuer. Therefore, the provider's decision is not subject to the internal claims and appeals and external review requirements under section 2719 of the PHS Act (incorporated into the Employee Retirement Income Security Act (ERISA) by section 715 of ERISA and the Internal Revenue Code (the Code) by section 9815 of the Code).

### **Notice Requirements**

Section 2715(d)(4) of the PHS Act and final rules issued by the Departments regarding the summary of benefits and coverage (SBC) provide that if a plan or issuer makes a material modification (as defined under section 102 of ERISA) in any of the terms of the plan or coverage that would affect the content of the SBC, that is not reflected in the most recently provided SBC, and that occurs other than in connection with a renewal or reissuance of coverage, the plan or issuer must provide notice of the modification to enrollees not later than 60 days prior to the date on which the modification will become effective.

On April 11, 2020, the Departments issued FAQs Part 42.<sup>13</sup> In FAQs Part 42, the Departments announced temporary enforcement relief so that a plan or issuer may add benefits or reduce or eliminate cost sharing for the diagnosis and treatment of COVID-19 or for telehealth and other remote care services during the PHE for COVID-19 or national emergency declaration period without providing 60 days' advance notice of a material modification. However, FAQs Part 42 stated that the plan or issuer must provide notice of the changes as soon as reasonably practicable.

---

<sup>13</sup> FAQs about Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Part 42 (Apr. 11, 2020), available at <https://www.dol.gov/sites/dolgov/files/ebsa/about-ebsa/our-activities/resource-center/faqs/aca-part-42.pdf> and <https://www.cms.gov/files/document/FFCRA-Part-42-FAQs.pdf>.



**Q11. Will the Departments take enforcement action when a plan or issuer covers qualifying coronavirus preventive services prior to satisfying the SBC notice of modification requirements?**

No. The Departments acknowledge that it would not be possible for plans and issuers to comply with the advance notice of modification requirements regarding qualifying coronavirus preventive services, as those services must be covered on the expedited timeframe specified by statute. Accordingly, the Departments will not take enforcement action against any plan or issuer that does not provide at least 60 days' advance notice of a material modification regarding the addition of coverage for qualifying coronavirus preventive services. However, plans and issuers must provide any required notice of the changes as soon as reasonably practicable. In addition, HHS encourages states to take a similar approach and will not consider a state to have failed to substantially enforce section 2715(d)(4) of the PHS Act if it takes such an approach.

**Excepted Benefits**

Sections 2722 and 2763 of the PHS Act, section 732 of ERISA, and section 9831 of the Code provide that the respective requirements of title XXVII of the PHS Act, part 7 of ERISA, and Chapter 100 of the Code generally do not apply to the provision of certain types of benefits, known as “excepted benefits.” Excepted benefits are described in section 2791(c) of the PHS Act, section 733(c) of ERISA, and section 9832(c) of the Code. These parallel statutory provisions establish four categories of excepted benefits, of which only the first and second are relevant here. The first category, under section 2791(c)(1) of the PHS Act, section 733(c)(1) of ERISA, and section 9832(c)(1) of the Code, includes benefits that are generally not health coverage, including on-site medical clinics. The benefits in this category are excepted in all circumstances.<sup>14</sup>

The second category of excepted benefits is limited excepted benefits, which may include limited scope vision or dental benefits, as well as benefits for long-term care, nursing home care, home health care, or community-based care. The benefits in this category are excepted only if certain conditions are met. Section 2791(c)(2)(C) of the PHS Act, section 733(c)(2)(C) of ERISA, and section 9832(c)(2)(C) of the Code authorize the Secretaries of HHS, Labor, and the Treasury (collectively, the Secretaries) to issue regulations establishing other, similar limited benefits as excepted benefits. The Secretaries exercised this authority previously with respect to certain employee assistance programs (EAPs).<sup>15</sup> Under the Departments' final regulations, EAPs are excepted if they satisfy all of the following requirements<sup>16</sup>:

(A) The EAP does not provide significant benefits in the nature of medical care. For this purpose, the amount, scope, and duration of covered services are taken into account.

---

<sup>14</sup> 26 CFR 54.9831-1(c)(2); 29 CFR 2590.732(c)(2); 45 CFR 146.145(b)(2) and 148.220(a).

<sup>15</sup> 79 FR 59130 (Oct. 1, 2014).

<sup>16</sup> 26 CFR 54.9831-1(c)(3)(vi); 29 CFR 2590.732(c)(3)(vi); 45 CFR 146.145(b)(3)(vi).

(B) The benefits under the EAP are not coordinated with benefits under another group health plan:

(1) Participants in the other group health plan must not be required to use and exhaust benefits under the EAP (making the EAP a gatekeeper) before an individual is eligible for benefits under the other group health plan; and

(2) Participant eligibility for benefits under the EAP must not be dependent on participation in another group health plan.

(C) No employee premiums or contributions are required as a condition of participation in the EAP.

(D) There is no cost sharing under the EAP.

FAQs Part 42, Q11 clarified that an employer may offer benefits for diagnosis and testing for COVID-19 under an EAP that constitutes an excepted benefit while a PHE declaration under section 319 of the PHS Act for COVID-19 or a national emergency declaration under the National Emergencies Act related to COVID-19 is in effect. FAQs Part 42, Q12 also clarified that an employer may offer benefits for diagnosis and testing for COVID-19 at an on-site medical clinic that constitutes an excepted benefit and that coverage of on-site medical clinics is an excepted benefit in all circumstances.

**Q12. May an employer offer benefits for COVID-19 vaccines (and their administration) under an EAP that constitutes an excepted benefit?**

Yes. The Departments' final regulations provide that for the purpose of determining whether an EAP provides benefits that are significant in the nature of medical care, the amount, scope, and duration of covered services are taken into account.<sup>17</sup> An EAP will not be considered to provide benefits that are significant in the nature of medical care solely because it offers benefits for COVID-19 vaccines and their administration (including when offered in combination with benefits for diagnosis and testing for COVID-19). However, there must be no cost sharing under the EAP for benefits under the EAP to constitute excepted benefits and the EAP must also comply with other applicable requirements.<sup>18</sup>

**Q13. May an employer offer benefits for COVID-19 vaccines (and their administration) at an on-site medical clinic that constitutes an excepted benefit?**

Yes. Coverage of on-site medical clinics is an excepted benefit in all circumstances.<sup>19</sup>

---

<sup>17</sup> *Id.*

<sup>18</sup> 26 CFR 54.9831-1(c)(3)(vi); 29 CFR 2590.732(c)(3)(vi); 45 CFR 146.145(b)(3)(vi).

<sup>19</sup> Section 9831(b) of the Code; section 732(b) of ERISA; section 2722(b) of the PHS Act.

## **Provider Relief Fund**

### **Q14. How should health care providers seek reimbursement when delivering COVID-19-related services to the uninsured?**

Congress provided and HHS administers two sources of federal funding to reimburse providers for providing services related to COVID-19 to uninsured patients. The FFCRA Relief Fund and the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA) collectively appropriated \$2 billion to reimburse providers for COVID-19 testing for uninsured individuals. Additionally, the CARES Act established a Provider Relief Fund (PRF) and appropriated \$100 billion to the fund. The PPPHCEA and the Coronavirus Response and Relief Supplemental Appropriations Act (CRRSA) collectively appropriated an additional \$78 billion in relief funds for a total of \$178 billion. A portion of the PRF is available to reimburse providers for COVID-19 testing and testing-related visits for uninsured individuals, treatment for uninsured individuals with a COVID-19 diagnosis, and COVID-19 vaccination administration fees via the Health Resources and Services Administration (HRSA) COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured program (referred to as the HRSA COVID-19 Uninsured Program). Providers are not required to ascertain a patient's immigration status in order to receive reimbursement from the fund.

HHS expects that providers will seek reimbursement from these funding sources for providing this care to the uninsured, thus helping to ensure that cost does not act as a barrier to needed services during the COVID-19 pandemic. HHS expects that providers will act in a manner consistent with state law and will not inappropriately leverage their greater knowledge of or familiarity with applicable reimbursement policy or withhold relevant information from consumers. Providers who receive reimbursement from the HRSA COVID-19 Uninsured Program cannot seek reimbursement, including balance billing, for such vaccination, care, or treatment from the individual or any other source.

Providers can familiarize themselves with this process at <https://www.hrsa.gov/coviduninsuredclaim>, and learn more and file claims at <https://coviduninsuredclaim.linkhealth.com/>. The Departments also seek input from stakeholders on potential strategies for directing uninsured people to providers who rely on reimbursement from the PRF and agree not to charge such patients for COVID-19 related services. Information regarding providers who have received claims reimbursement for COVID-19 testing of uninsured individuals and/or treatment for uninsured individuals with a COVID-19 diagnosis is available at <https://data.cdc.gov/Administrative/Claims-Reimbursement-to-Health-Care-Providers-and-/rksx-33p3>.